BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...three candidates in Phase III testing: anti-HER2 mAb GB221 for metastatic breast cancer, infliximab biosimilar GB242...
...cell death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar infliximab (GB242) Biosimilar...
Items per page:
1 - 1 of 1